Evidence map›Paper›PMID 38309955›Full record

ArticleCardiovascular research2024

ISG15 blocks cardiac glycolysis and ensures sufficient mitochondrial energy production during Coxsackievirus B3 infection.

Clara Bredow, Fabien Thery, Eva Katrin Wirth, Sarah Ochs, Meike Kespohl, Gunnar Kleinau, Nicolas Kelm, Niclas Gimber, Jan Schmoranzer, Martin Voss and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. When ISG15 is involved in inflammation.Frontiers in immunology · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. ISGylation: is our genome yearning for such a modification?Acta biochimica et biophysica Sinica · 2025
    Review
  18. Interferons and interferon-related pathways in heart disease.Frontiers in cardiovascular medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 2 countries.

Clara BredowCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.
Fabien TheryDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Eva Katrin WirthDeutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Sarah OchsCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.
Meike KespohlCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.
Gunnar KleinauCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charitéplatz 1, Berlin, Germany.
Nicolas KelmCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.
Niclas GimberCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany.
Jan SchmoranzerCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany.
Martin VossCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.
Karin KlingelUniversity of Tübingen, Cardiopathology, Institute for Pathology and Neuropathology, Tübingen, Germany.
Joachim SprangerDeutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Kostja RenkoGerman Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), Berlin, Germany.
Markus RalserCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility-High-Throughput Mass Spectrometry, Berlin, Germany.ORCID 0000-0001-9535-7413
Michael MüllederCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility-High-Throughput Mass Spectrometry, Berlin, Germany.
Arnd HeuserMax-Delbrueck-Center (MDC) for Molecular Medicine, Animal Phenotyping Platform, Berlin, Germany.
Klaus-Peter KnobelochUniversity of Freiburg, Institute of Neuropathology, Freiburg, Germany.
Patrick ScheererDeutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany.
Jennifer KirwanBerlin Institute of Health at Charité Universitätsmedizin, Metabolomics, Charitéplatz 1 Berlin 10117, Germany.
Ulrike BrüningBerlin Institute of Health at Charité Universitätsmedizin, Metabolomics, Charitéplatz 1 Berlin 10117, Germany.
Nikolaus BerndtGerman Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Department of Molecular Toxicology, Nuthetal, Germany.ORCID 0000-0001-5594-9940
Francis ImpensDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Antje BelingCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Charitéplatz 1, 10117 Berlin, Germany.ORCID 0000-0002-1826-5248
Charité - Universitätsmedizin Berlin · DEGerman Centre for Cardiovascular Research · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEGhent University · BEFederal Institute for Risk Assessment · DEHumboldt-Universität zu Berlin · DEMax Delbrück Center · DEUniversity of Freiburg · DEUniversity of Tübingen · DE

Funding

Advanced Medical Bioimaging Core FacilityBundesministerium für Bildung und ForschungCharité -UniversitätsmedizinFoundation for Experimental Biomedicine Zurich, SwitzerlandGerman Federal Ministry of Education and Research 031A427AGerman Research Foundation 39/1216-1International Max Planck Research School for Infectious Diseases and Immunology SFB958/Z02Research Foundation Flanders G0F8616N
6 · The paper itself

Abstract

aimsVirus infection triggers inflammation and, may impose nutrient shortage to the heart. Supported by type I interferon (IFN) signalling, cardiomyocytes counteract infection by various effector processes, with the IFN-stimulated gene of 15 kDa (ISG15) system being intensively regulated and protein modification with ISG15 protecting mice Coxsackievirus B3 (CVB3) infection. The underlying molecular aspects how the ISG15 system affects the functional properties of respective protein substrates in the heart are unknown. METHODS AND

resultsBased on the protective properties due to protein ISGylation, we set out a study investigating CVB3-infected mice in depth and found cardiac atrophy with lower cardiac output in ISG15-/- mice. By mass spectrometry, we identified the protein targets of the ISG15 conjugation machinery in heart tissue and explored how ISGylation affects their function. The cardiac ISGylome showed a strong enrichment of ISGylation substrates within glycolytic metabolic processes. Two control enzymes of the glycolytic pathway, hexokinase 2 (HK2) and phosphofructokinase muscle form (PFK1), were identified as bona fide ISGylation targets during infection. In an integrative approach complemented with enzymatic functional testing and structural modelling, we demonstrate that protein ISGylation obstructs the activity of HK2 and PFK1. Seahorse-based investigation of glycolysis in cardiomyocytes revealed that, by conjugating proteins, the ISG15 system prevents the infection-/IFN-induced up-regulation of glycolysis. We complemented our analysis with proteomics-based advanced computational modelling of cardiac energy metabolism. Our calculations revealed an ISG15-dependent preservation of the metabolic capacity in cardiac tissue during CVB3 infection. Functional profiling of mitochondrial respiration in cardiomyocytes and mouse heart tissue by Seahorse technology showed an enhanced oxidative activity in cells with a competent ISG15 system.

conclusionOur study demonstrates that ISG15 controls critical nodes in cardiac metabolism. ISG15 reduces the glucose demand, supports higher ATP production capacity in the heart, despite nutrient shortage in infection, and counteracts cardiac atrophy and dysfunction.

Indexed as

Coxsackievirus InfectionsCytokinesEnergy MetabolismGlycolysisMitochondria, HeartMyocytes, CardiacUbiquitinsAnimalsDisease Models, AnimalEnterovirus B, HumanHost-Pathogen InteractionsHumansMaleMice, Inbred C57BLMice, KnockoutProtein Processing, Post-TranslationalCytokinesG1p2 protein, mouseUbiquitinsGlycolysisISG15ISGylationMetabolismMitochondrial functionVirus infection

Identifiers

PMID38309955
PMCPMC11074791
OpenAlexW4391517817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.